Progress in Cardiovascular Diseases
Volume 49, Issue 2 , Pages 76-87 , September 2006

β-Blockers for Primary Prevention in Hypertension: Era Bygone?

  • Gurusher S. Panjrath
    • ,
  • Franz H. Messerli

      Affiliations

    • Corresponding Author InformationAddress reprint request: Franz H. Messerli, MD, Division of Cardiology, St. Luke's Roosevelt Hospital, Suite 3B.30, 1000 10th Avenue, New York, NY 10019.

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003;289:2560–2572
  2. Cruickshank JM, PB . Beta-blockers in clinical practice. In: 2nd ed. Churchill-Livingstone: Edinburgh; 1994;p. 1–1204
  3. McDevitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur. Heart. J. 1987;8(Suppl M):9–14
  4. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on antihypertensive agents. JAMA. 1982;248:2004–2011
  5. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br. Med. J. (Clin Res Ed). 1985;291:97–104
  6. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J. Hypertens. 1985;3:379–392
  7. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. (Clin Res Ed). 1986;293:1145–1151
  8. Berglund G, Andersson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med. Scand. 1986;220:419–424
  9. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial. J. Hypertens. 1987;5:561–572
  10. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281–1285
  11. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am. J. Hypertens. 1992;5(6 Pt 2):182S–189S
  12. Medical Research Council trial of treatment of hypertension in older adults: Principal results. MRC working party. BMJ. 1992;304:405–412
  13. Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: A fourteen-year follow-up study. Cerebrovasc. Dis. 2001;12:171–180
  14. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non–insulin dependent diabetes followed for three years. Bmj. 1995;310:83–88
  15. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  16. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension–2 study. Lancet. 1999;354:1751–1756
  17. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365
  18. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422–2427
  19. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421–2431
  20. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003
  21. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke. 1993;24:543–548
  22. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073–2082
  23. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003;290:2805–2816
  24. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895–906
  25. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice?. Lancet. 2004;364:1684–1689
  26. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–1553
  27. Beevers DG. The end of beta blockers for uncomplicated hypertension?. Lancet. 2005;366:1510–1512
  28. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:1903–1907
  29. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis. CMAJ. 2006;174:1737–1742
  30. Messerli FH, Sundgaard-Riise K, Ventura HO, et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet. 1983;2:983–986
  31. Weber K, Bohmeke T, van der Does R, et al. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc. Drugs Ther. 1996;10:113–117
  32. Grossman E, Messerli FH. Why beta-blockers are not cardioprotective in elderly patients with hypertension. Curr. Cardiol. Rep. 2002;4:468–473
  33. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 2003;115:41–46
  34. Schulman SP, Weiss JL, Becker LC, et al. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N. Engl. J. Med. 1990;322:1350–1356
  35. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA. 1981;246:2073–2074
  36. Pedersen TR. The Norwegian multicenter study of timolol after myocardial infarction. Circulation. 1983;67(6 Pt 2):I49–I53
  37. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–1390
  38. Houghton T, Freemantle N, Cleland JGF. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur. J. Heart Fail. 2000;2:333–340
  39. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814–2819
  40. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 1998;339:489–497
  41. Mickley H, Eiskjaer H, Botker HE. Is an additional post-myocardial infarction beta-blocker trial required in the era of early revascularization?. Eur. Heart J. 2004;25:96–97
  42. Chen ZM, Pan HC, Chen YP, et al. Commit (CLOPIDOGREL and METOPROLOL in Myocardial Infarction Trial) Collaboration Group. Lancet. 2005;366:1622–1632
  43. Bengtsson C, Blohme G, Lapidus L, et al. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: A 12-year prospective population study of women in Gothenburg, Sweden. J. Intern. Med. 1992;231:583–588
  44. Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–1157
  45. Ehmer B, van der Does R, Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non–insulin-dependent diabetics. Drugs. 1988;36(Suppl 6):136–140
  46. Poirier L, Cleroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. 2001;19:1429–1435
  47. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet. 2003;362:7–13
  48. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA. 2004;292:2227–2236
  49. Vernon C, Sakula A. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol. Br. J. Clin. Pract. 1979;33:112–121
  50. Messerli FH, Beevers DG, Franklin SS, et al. beta-Blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am. J. Hypertens. 2003;16:870–873
  51. Heitmann M, Davidsen U, Stokholm KH, et al. Renal and cardiac function during alpha1-beta–blockade in congestive heart failure. Scand. J. Clin. Lab. Invest. 2002;62:97–104
  52. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am. Heart J. 1988;116(2 Pt 1):515–523
  53. Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990;263:1653–1657
  54. Cruickshank JM. Beta-blockers continue to surprise us. Eur. Heart J. 2000;21:354–364
  55. Grimm RH. Antihypertensive therapy: taking lipids into consideration. Am. Heart J. 1991;122(3 Pt 2):910–918
  56. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J. Am. Coll. Cardiol. 2001;7:1950–1956
  57. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2:539–543
  58. Messerli FH, Grossman E. Beta-blocker therapy and depression. JAMA. 2002;16 288:1845–1846[author reply 1846]
  59. Salem SA, McDevitt DG. Central effects of beta-adrenoceptor antagonists. Clin. Pharmacol. Ther. 1983;33:52–57
  60. Messerli FH, Grossman E. Beta-blockers in hypertension: Is carvedilol different?. Am. J. Cardiol. 2004;93:7B–12B
  61. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–1225
  62. Kelly R, Daley J, Avolio A, et al. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension. 1989;14:14–21

PII: S0033-0620(06)00084-3

doi: 10.1016/j.pcad.2006.07.002

Progress in Cardiovascular Diseases
Volume 49, Issue 2 , Pages 76-87 , September 2006

Article Tools

* Image Usage & Resolution